Dataset Viewer
Auto-converted to Parquet Duplicate
chunk_id
stringlengths
23
27
chunk
stringlengths
40
4.57k
source_url
stringclasses
246 values
title
stringclasses
246 values
chunk_idx
int64
0
68
chunk_start_char
int64
0
20.9k
chunk_end_char
int64
49
21k
0000051434-25-000060#s65
On August 20, 2025, International Paper Company (the “ Company ”) committed to mill closures at its Riceboro, Georgia and Savannah, Georgia facilities impacting its Containerboard business.
0000051434-25-000060
International Paper 8-K 2025-08-21
0
65
254
0000051434-25-000060#s255
The Company estimates the closures will result in aggregate pre-tax cash charges of approximately $158 million and pre-tax non-cash accelerated depreciation charges of approximately $570 million as further described below.
0000051434-25-000060
International Paper 8-K 2025-08-21
1
255
287
0000051434-25-000060#s478
These actions are being undertaken as part of the Company’s 80/20 strategic approach, as announced by the Company in July 2024.
0000051434-25-000060
International Paper 8-K 2025-08-21
2
478
192
0000051434-25-000060#s606
Through the 80/20 strategic approach, we intend to deliver profitable market share growth by striving to be the lowest-cost producer and the most reliable and innovative sustainable packaging solutions provider to our customers across North America and EMEA.
0000051434-25-000060
International Paper 8-K 2025-08-21
3
606
864
0000051434-25-000060#s865
As part of the Company’s 80/20 strategic approach, the Company intends to guide investments and align resources to win with our most strategic customers, while reducing complexity and cost across the Company.
0000051434-25-000060
International Paper 8-K 2025-08-21
4
865
814
0000051434-25-000060#s1074
Riceboro, Georgia Mill The Company plans to permanently close its containerboard, timber and lumber mills in Riceboro, Georgia.
0000051434-25-000060
International Paper 8-K 2025-08-21
5
1,074
1,201
0000051434-25-000060#s1202
The containerboard mill will shut down in stages with all operations expected to cease by September 12, 2025.
0000051434-25-000060
International Paper 8-K 2025-08-21
6
1,202
1,183
0000051434-25-000060#s1312
The closure is expected to reduce the Company’s containerboard capacity by approximately 430,000 tons.
0000051434-25-000060
International Paper 8-K 2025-08-21
7
1,312
1,176
0000051434-25-000060#s1415
The Company estimates that the closure will result in aggregate pre-tax noncash asset write-off and accelerated depreciation charges of approximately $170 million and aggregate pre-tax cash severance and other shutdown charges of approximately $77 million, and anticipates that these charges will be recorded during the ...
0000051434-25-000060
International Paper 8-K 2025-08-21
8
1,415
1,433
0000051434-25-000060#s1775
The Company expects closure of the containerboard mill to reduce its workforce by approximately 300 employees.
0000051434-25-000060
International Paper 8-K 2025-08-21
9
1,775
1,184
0000051434-25-000060#s1886
Savannah, Georgia Mill The Company plans to permanently close its containerboard mill and packaging facility in Savannah, Georgia.
0000051434-25-000060
International Paper 8-K 2025-08-21
10
1,886
2,016
0000051434-25-000060#s2017
The containerboard mill will shut down in stages with all operations expected to cease by September 30, 2025.
0000051434-25-000060
International Paper 8-K 2025-08-21
11
2,017
1,995
0000051434-25-000060#s2127
The closure is expected to reduce the Company’s containerboard capacity by approximately 1,000,000 tons.
0000051434-25-000060
International Paper 8-K 2025-08-21
12
2,127
1,990
0000051434-25-000060#s2232
The Company estimates that the closure will result in aggregate pre-tax noncash asset write-off and accelerated depreciation charges of approximately $400 million and aggregate pre-tax cash severance and other shutdown charges of approximately $81 million, and anticipates that these charges will be recorded during the ...
0000051434-25-000060
International Paper 8-K 2025-08-21
13
2,232
2,245
0000051434-25-000060#s2592
The Company expects closure of the containerboard mill to reduce its workforce by approximately 680 employees.
0000051434-25-000060
International Paper 8-K 2025-08-21
14
2,592
1,996
0000051434-25-000060#s2737
The disclosure under Item 2.05 is incorporated by reference into this item 2.06.
0000051434-25-000060
International Paper 8-K 2025-08-21
15
2,737
2,817
0000051434-25-000060#s2859
On August 21, 2025, the Company issued a press release announcing these actions, which is attached as Exhibit 99.1 and is incorporated herein by reference.
0000051434-25-000060
International Paper 8-K 2025-08-21
16
2,859
3,014
0000051434-25-000060#s3015
The information furnished pursuant to this Item 7.01, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the ...
0000051434-25-000060
International Paper 8-K 2025-08-21
17
3,015
3,409
0000051434-25-000060#s3439
This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding, among other things, our closures and associated headcount reduction as well as anticipated expense reductions, the expected amount of certain pre-tax cha...
0000051434-25-000060
International Paper 8-K 2025-08-21
18
3,439
3,882
0000051434-25-000060#s3883
These forward-looking statements reflect management's current views and are subject to risks and uncertainties that could cause actual results and the timing of events to differ materially from those expressed or implied in these forward-looking statements.
0000051434-25-000060
International Paper 8-K 2025-08-21
19
3,883
3,696
0000051434-25-000060#s4141
Factors which could cause actual results to differ from such forward-looking statements include, but are not limited to, industry, global, economic and other conditions, as well as other factors, that could affect the closures including the amount of such pre-tax charges and the timing of such pre-tax charges or action...
0000051434-25-000060
International Paper 8-K 2025-08-21
20
4,141
3,778
0000051434-25-000060#s4481
These forward-looking statements are also subject to the risks and uncertainties relating to the business of the Company contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC") on February 21, 2025, the Company...
0000051434-25-000060
International Paper 8-K 2025-08-21
21
4,481
3,987
0000051434-25-000060#s5030
In addition, other risks and uncertainties not presently known to the Company or that we currently believe to be immaterial could affect the accuracy of any forward-looking statements.
0000051434-25-000060
International Paper 8-K 2025-08-21
22
5,030
3,623
0000051434-25-000060#s5215
The Company undertakes no obligation to publicly update any forward-looking statements contained in this Current Report on Form 8-K, whether as a result of new information, future events or changes in expectations.
0000051434-25-000060
International Paper 8-K 2025-08-21
23
5,215
3,653
0000051434-25-000060#s5505
Number Description 99.1 International Paper Company Press Release dated August 21, 2025.
0000051434-25-000060
International Paper 8-K 2025-08-21
24
5,505
5,593
0000051434-25-000060#s5594
104 The cover page from this Current Report on Form 8-K, formatted as inline XBRL.
0000051434-25-000060
International Paper 8-K 2025-08-21
25
5,594
5,676
0000950170-24-059539#s57
On May 14, 2024, Tenaya Therapeutics, Inc. (“Tenaya”) issued a press release announcing Tenaya’s financial results for the quarter ended March 31, 2024 (“the Earnings Press Release”).
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
0
57
240
0000950170-24-059539#s241
The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
1
241
176
0000950170-24-059539#s361
All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securit...
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
2
361
797
0000950170-24-059539#s859
On May 14, 2024, Tenaya announced cost containment measures, including a committed plan to reduce its workforce (the “Workforce Reduction”).
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
3
859
999
0000950170-24-059539#s1000
The cost containment measures align with Tenaya’s focus on generating data from its clinical-stage gene therapy programs.
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
4
1,000
980
0000950170-24-059539#s1122
Employees impacted by the Workforce Reduction were notified on May 13, 2024, and represent approximately 22% of the workforce.
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
5
1,122
1,248
0000950170-24-059539#s1249
In connection with the Workforce Reduction, Tenaya estimates that it will incur approximately $1.3 million to $1.5 million, of aggregate charges, primarily related to employee cash severance and continuing health benefits, which costs are expected to be substantially recognized during the second quarter of 2024.
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
6
1,249
1,435
0000950170-24-059539#s1563
The foregoing estimates that Tenaya expects to incur in connection with the Workforce Reduction are contingent upon various assumptions and actual results may differ.
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
7
1,563
1,729
0000950170-24-059539#s1730
Tenaya may also incur additional costs not currently contemplated due to events related to or resulting from the Workforce Reduction.
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
8
1,730
1,696
0000950170-24-059539#s1864
A copy of the press release announcing the cost containment measures is attached as Exhibit 99.1 to this Current Report on Form 8-K.
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
9
1,864
1,996
0000950170-24-059539#s2026
This Current Report on Form 8-K contains forward-looking statements, including statements regarding the continued development of Tenaya’s clinical-stage gene therapy programs and the implementation of the Workforce Reduction, including expected charges relating thereto and the objectives and anticipated timing thereof.
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
10
2,026
2,346
0000950170-24-059539#s2347
Actual results may differ from those set forth in or implied by this Current Report on Form 8-K due to the risks and uncertainties associated with Tenaya’s ability to conduct clinical trials of TN-201 and TN-401 sufficient to achieve a positive completion; risks related to the potential failure of TN-201 and TN-401 to ...
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
11
2,347
2,951
0000950170-24-059539#s3273
You are cautioned not to place undue reliance on these forward-looking statements.
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
12
3,273
2,108
0000950170-24-059539#s3356
Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and Tenaya specifically disclaims any obligation to update any forward-looking statement, except as required by law.
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
13
3,356
2,252
0000950170-24-059539#s3656
Description 99.1 Press Release of Tenaya Therapeutics, Inc., dated May 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
0000950170-24-059539
Tenaya Therapeutics 8-K 2024-05-14
14
3,656
3,811
0001193125-22-167332#s63
On May 31, 2022, the board of directors (the “Board”) of Verrica Pharmaceuticals Inc. (the “Company”), in order to streamline operations and reduce costs, approved a plan to reduce its workforce by terminating 20 employees, which the Company expects to be completed by June 3, 2022.
0001193125-22-167332
Verrica Pharmaceuticals 8-K 2022-06-03
0
63
345
0001193125-22-167332#s346
The decision followed the Company’s announcement on May 24, 2022 of the receipt by the Company of a complete response letter for its new drug application for VP-102.
0001193125-22-167332
Verrica Pharmaceuticals 8-K 2022-06-03
1
346
228
0001193125-22-167332#s512
As a result, the Company expects to incur a one-time charge totaling approximately $0.5 million in connection with one-time employee termination costs.
0001193125-22-167332
Verrica Pharmaceuticals 8-K 2022-06-03
2
512
663
0001193125-22-167332#s664
The Company expects such costs to be the only direct expense of the restructuring plan.
0001193125-22-167332
Verrica Pharmaceuticals 8-K 2022-06-03
3
664
599
0001193125-22-167332#s752
This charge is expected to be incurred during the quarter ending June 30, 2022, with related cash payments expected to be substantially paid out by June 30, 2022.
0001193125-22-167332
Verrica Pharmaceuticals 8-K 2022-06-03
4
752
674
0001193125-22-167332#s915
The estimates of costs that the Company expects to incur and the timing thereof are subject to a number of assumptions and actual results may differ.
0001193125-22-167332
Verrica Pharmaceuticals 8-K 2022-06-03
5
915
1,064
0001213900-23-008435#s63
On February 1, 2023, Cyren Ltd. (the “Company”) approved a plan to reduce the workforce of the Company and its subsidiaries by approximately 121 employees in the aggregate, representing substantisally all of the Company’s and its subsidiaries’ total global workforce.
0001213900-23-008435
Cyren 8-K 2023-02-06
0
63
330
0001213900-23-008435#s331
This decision was based on cost-reduction initiatives intended to reduce operating expenses.
0001213900-23-008435
Cyren 8-K 2023-02-06
1
331
155
0001213900-23-008435#s424
The Company currently estimates that it will incur one-time cash charges of a maximum of up to approximately $3,600,000.00 in connection with the reduction in force, primarily consisting of accrued paid time off, notice period payments, employee benefits and related costs.
0001213900-23-008435
Cyren 8-K 2023-02-06
2
424
697
0001213900-23-008435#s698
The Company expects the majority of charges will be incurred in the first quarter of 2023, subject to local law requirements, which may extend the process beyond the first quarter 2023 in certain countries.
0001213900-23-008435
Cyren 8-K 2023-02-06
3
698
630
0001213900-23-008435#s905
The charges the Company expects to incur are subject to assumptions, including local law requirements and availability of funds to satisfy payment obligations, and actual charges may differ from the estimate disclosed above.
0001213900-23-008435
Cyren 8-K 2023-02-06
4
905
648
0001213900-23-008435#s1130
A copy of the press release issued by the Company on February 1, 2023 announcing the reduction in force is attached hereto as Exhibit 99.1 and incorporated herein by reperence.
0001213900-23-008435
Cyren 8-K 2023-02-06
5
1,130
1,306
0001213900-23-008435#s1357
Information Certain statements in this Current Report on Form 8-K constitute “forward-looking statements” within the meaning of the federal securities laws.
0001213900-23-008435
Cyren 8-K 2023-02-06
6
1,357
1,513
0001213900-23-008435#s1514
These statements are based on management’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results.
0001213900-23-008435
Cyren 8-K 2023-02-06
7
1,514
1,529
0001213900-23-008435#s1687
These forward-looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions.
0001213900-23-008435
Cyren 8-K 2023-02-06
8
1,687
1,501
0001213900-23-008435#s1832
Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements.
0001213900-23-008435
Cyren 8-K 2023-02-06
9
1,832
1,531
0001213900-23-008435#s2007
While the Company believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results.
0001213900-23-008435
Cyren 8-K 2023-02-06
10
2,007
1,574
0001213900-23-008435#s2225
There are many risks and uncertainties that could cause actual results to differ materially from forward-looking statements made herein including the risks discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the Company’s Quarterly Report on Fo...
0001213900-23-008435
Cyren 8-K 2023-02-06
11
2,225
1,844
0001213900-23-008435#s2713
Such forward-looking statements are made only as of the date of this Current Report on Form 8-K.
0001213900-23-008435
Cyren 8-K 2023-02-06
12
2,713
1,453
0001213900-23-008435#s2810
The Company undertakes no obligation to publicly update or revise any forward-looking statement because of new information, future events or otherwise, except as otherwise required by law.
0001213900-23-008435
Cyren 8-K 2023-02-06
13
2,810
1,545
0001213900-23-008435#s2999
If it does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.
0001213900-23-008435
Cyren 8-K 2023-02-06
14
2,999
1,547
0001213900-23-008435#s3267
99.1 Press Release issued by Cyren Ltd. on February 1, 2023.
0001213900-23-008435
Cyren 8-K 2023-02-06
15
3,267
3,327
0001213900-23-008435#s3328
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
0001213900-23-008435
Cyren 8-K 2023-02-06
16
3,328
3,408
0001493152-23-006122#s311
The overall controlled environment agriculture market is also experiencing a fluctuating economy, rising costs, and the fear of recession that is delaying, reducing or eliminating capital projects.
0001493152-23-006122
CEA Industries 8-K 2023-02-27
0
311
197
0001493152-23-006122#s509
Additionally, the Company faces continued supply chain, labor and inflationary issues that are impacting customers’ contract decisions and implementation.
0001493152-23-006122
CEA Industries 8-K 2023-02-27
1
509
154
0001493152-23-006122#s664
As a result, the Company has taken cost saving initiatives to reduce operating expenses and to reduce its workforce so as to preserve working capital and liquidity without compromising the servicing of Company clients.
0001493152-23-006122
CEA Industries 8-K 2023-02-27
2
664
218
0001493152-23-006122#s1013
Description 99.1 Press Release dated February 27, 2023, relating to cost saving initiatives 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
0001493152-23-006122
CEA Industries 8-K 2023-02-27
3
1,013
1,180
0001628280-25-050671#s61
On November 6, 2025, Kezar Life Sciences, Inc. (the “Company”) implemented a restructuring plan pursuant to which the Company will reduce its workforce by approximately 31 employees, or approximately 70%.
0001628280-25-050671
Kezar Life Sciences 8-K 2025-11-07
0
61
265
0001628280-25-050671#s266
The Company implemented this restructuring plan in connection with its previously announced evaluation of strategic alternatives.
0001628280-25-050671
Kezar Life Sciences 8-K 2025-11-07
1
266
190
0001628280-25-050671#s396
The Company estimates that it will incur cash expenditures of approximately $6.0 million, consisting primarily of one-time severance payments, benefits and other related costs.
0001628280-25-050671
Kezar Life Sciences 8-K 2025-11-07
2
396
237
0001628280-25-050671#s573
The Company expects to recognize the majority of such costs in the fourth quarter of 2025.
0001628280-25-050671
Kezar Life Sciences 8-K 2025-11-07
3
573
151
0001628280-25-050671#s664
The estimated costs that the Company expects to incur, and the timing thereof, are subject to a number of assumptions, and actual amounts may differ materially.
0001628280-25-050671
Kezar Life Sciences 8-K 2025-11-07
4
664
221
0001628280-25-050671#s825
The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction.
0001628280-25-050671
Kezar Life Sciences 8-K 2025-11-07
5
825
230
0001628280-25-050671#s995
If required, the Company will amend this Current Report on Form 8-K at such time as its management is able in good faith to estimate the amount, or range of amounts, of these additional charges.
0001628280-25-050671
Kezar Life Sciences 8-K 2025-11-07
6
995
255
0001193125-25-085773#s63
On April 17, 2025, Tempest Therapeutics, Inc. (the “Company”) adopted a plan to extend its capital resources in connection with initiating the previously announced process to explore a full range of strategic alternatives.
0001193125-25-085773
Tempest Therapeutics 8-K 2025-04-18
0
63
285
0001193125-25-085773#s286
As part of the plan, the Company will reduce its workforce by 21 of 26 full-time employees, effective April 30, 2025.
0001193125-25-085773
Tempest Therapeutics 8-K 2025-04-18
1
286
180
0001193125-25-085773#s404
The Company anticipates that key employees within this group will transition to consulting agreements and continue to be available to the Company.
0001193125-25-085773
Tempest Therapeutics 8-K 2025-04-18
2
404
209
0001193125-25-085773#s551
The Company estimates that it will incur approximately $1.5 million of cash expenditures, consisting primarily of one-time severance payments, benefits and other related costs (excluding non-cash charges associated with equity-based compensation), with the majority of such costs to be incurred in the second quarter of ...
0001193125-25-085773
Tempest Therapeutics 8-K 2025-04-18
3
551
388
0001193125-25-085773#s877
The estimated costs that the Company expects to incur, and the timing thereof, are subject to a number of assumptions and actual results may differ.
0001193125-25-085773
Tempest Therapeutics 8-K 2025-04-18
4
877
211
0001193125-25-085773#s1026
The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction, including potential impairment charges, if any.
0001193125-25-085773
Tempest Therapeutics 8-K 2025-04-18
5
1,026
289
0001193125-25-085773#s1253
However, the Company is not able to estimate the amount or range of amounts of such potential impairments as of the date of this Current Report on Form 8-K.
0001193125-25-085773
Tempest Therapeutics 8-K 2025-04-18
6
1,253
219
0001193125-25-085773#s1410
If required, the Company will amend this Current Report on Form 8-K at such time as its management is able in good faith to estimate the amount, or range of amounts, of these charges.
0001193125-25-085773
Tempest Therapeutics 8-K 2025-04-18
7
1,410
246
0001493152-22-003287#s268
As a result, the Company anticipates terminating twelve (12) employees in the United States and twenty-three (23) in its Mexico offices (the “Terminations”).
0001493152-22-003287
Bigtoken 8-K 2022-02-04
0
268
157
0001493152-22-003287#s426
As a result of the Terminations, the Company will (i) reduce its workforce by approximately seventy percent 70% in total and (ii) reduce its annual payroll by $2.09 million or approximately fifty seven percent (57%).
0001493152-22-003287
Bigtoken 8-K 2022-02-04
1
426
216
0001493152-22-003287#s643
The Terminations, which will be effective February 15, 2022, were part of a broad set of cost-saving measures implemented by new management subsequent to the completion of its merger with BritePool, Inc. that closed on November 30, 2021.
0001493152-22-003287
Bigtoken 8-K 2022-02-04
2
643
237
0001493152-22-003287#s881
The Company estimates that the pre-tax costs for the Terminations will be in the range of $80,000 to $150,000, substantially all of which are related to employee severance (the “Severances”), which the Company expects to record in the quarter ending March 31, 2022.
0001493152-22-003287
Bigtoken 8-K 2022-02-04
3
881
265
0001493152-22-003287#s1147
The Company does not anticipate any future cash expenditures beyond the payment of the Severances.
0001493152-22-003287
Bigtoken 8-K 2022-02-04
4
1,147
98
0001493152-22-003287#s1488
These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties.
0001493152-22-003287
Bigtoken 8-K 2022-02-04
5
1,488
1,555
0001493152-22-003287#s1629
The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to cost reduction efforts.
0001493152-22-003287
Bigtoken 8-K 2022-02-04
6
1,629
1,672
0001493152-22-003287#s1887
In addition, the Company’s workforce reduction costs may be greater than anticipated and the workforce reduction may have an adverse impact on the Company’s development activities.
0001493152-22-003287
Bigtoken 8-K 2022-02-04
7
1,887
1,595
0001493152-22-003287#s2068
A further description of the risks and uncertainties relating to the business of the Company is contained in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the Securities and Exchange Commission (the “SEC”) on November 15, 2021, and the Company’s subsequent cur...
0001493152-22-003287
Bigtoken 8-K 2022-02-04
8
2,068
2,420
0001493152-22-003287#s2421
The Company undertakes no duty or obligation to update any forward-looking statements contained in this Item 2.05 as a result of new information, future events or changes in its expectations.
0001493152-22-003287
Bigtoken 8-K 2022-02-04
9
2,421
2,259
0001115128-22-000036#s62
On November 15, 2022, Quotient Technology Inc. (“Quotient”) initiated a workforce reduction plan in connection with its ongoing business transformation efforts.
0001115128-22-000036
Quotient Technology 8-K 2022-11-16
0
62
222
0001115128-22-000036#s223
Quotient will reduce its workforce in the United States, United Kingdom, and India across all functions by approximately 82 employees.
0001115128-22-000036
Quotient Technology 8-K 2022-11-16
1
223
196
0001115128-22-000036#s358
This represents a reduction of approximately nine percent (9%) of Quotient’s regular full-time global workforce and approximately fourteen percent (14%) of Quotient’s U.S.-based workforce.
0001115128-22-000036
Quotient Technology 8-K 2022-11-16
2
358
250
0001115128-22-000036#s547
In connection with this plan, Quotient estimates that it will recognize total pre-tax restructuring charges to its GAAP financial results in the approximate amount of $2 million consisting of severance and other one-time termination benefits.
0001115128-22-000036
Quotient Technology 8-K 2022-11-16
3
547
789
0001115128-22-000036#s827
Quotient expects that these charges will be recognized in the fourth quarter of fiscal 2022.
0001115128-22-000036
Quotient Technology 8-K 2022-11-16
4
827
639
0001115128-22-000036#s920
The foregoing contains forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
0001115128-22-000036
Quotient Technology 8-K 2022-11-16
5
920
1,075
0001115128-22-000036#s1076
These forward-looking statements include the amount of, and timing of, workforce-related charges and the status of Quotient’s business transformation efforts.
0001115128-22-000036
Quotient Technology 8-K 2022-11-16
6
1,076
1,078
End of preview. Expand in Data Studio

EDGAR 8-K — Context Chunk Retrieval (coreference + near-duplicate)

A contextualized sentence-level (query2chunk) retrieval eval built from SEC 8-K restructuring filings (EDGAR), for the Chunk-level Retrieval Eval collection.

Why this benchmark exists. Standard passage benchmarks (e.g. DAPR) don't discriminate contextual embedding models, because their answer passages already contain the distinguishing entity and have no near-duplicate distractors. This dataset is built to stress document-context disambiguation:

  • Sentence chunks are coreference-dependent — the answer sentence says "the Company", never the company name, so resolving it requires the surrounding document.
  • Near-identical distractors across companies — 8-Ks are templated, so the corpus holds dozens of near-identical sentences like "the Company estimates that it will incur charges of approximately $X million" differing only by amount/company. In isolation these are indistinguishable; only the document context resolves which "Company" is meant.

Example — query "What restructuring charges does Elastic expect to incur?" → answer "The Company expects to incur total non-recurring cash charges of approximately $22 million to $25 million…" competes against 58 near-identical charge sentences from other filings.

Stats

count
documents (filings) 246
corpus (sentence chunks) 4,936
queries 38 (28 with a supporting-evidence fragment)
near-duplicate charge sentences 58
near-duplicate workforce sentences 53

Graded gold: answer vs supporting evidence

Gold is graded via the standard score field (no schema change vs the rest of the collection):

score role meaning
2 answer the sentence that directly answers the query (uses coreference)
1 evidence a supporting fact that disambiguates the answer (e.g. the sentence binding the company name to "the Company")

Derive the two metrics from one qrels:

standard_recall@k = |topk ∩ {score >= 2}| / |{score >= 2}|   # answer only
evidence_recall@k = |topk ∩ {score >= 1}| / |{score >= 1}|   # answer + supporting evidence

nDCG@k can consume the graded scores directly. A human-readable roles field (answer / evidence) mirrors the score. Backward compatible: datasets that use score = 1 uniformly are answer-only (no evidence tier).

Configs

documents

chunk_id, chunk (one sentence), source_url (filing accession — group chunks by this to give a contextual model its document view), title (company + 8-K date), chunk_idx (sentence position in the filing), chunk_start_char / chunk_end_char.

queries

original_query / query, answer[] (gold sentence texts), score[] (2=answer, 1=evidence), source_url[] (filing per gold), frag_start_char[] / frag_end_char[], n_gold, roles[] (answer/evidence), fact (workforce / charges).

Gold matching: a chunk is gold for a query if it shares source_url and its [chunk_start_char, chunk_end_char) overlaps a gold fragment's span (each gold maps to exactly one sentence chunk).

Construction & limitations

Built from EDGAR full-text search for restructuring 8-Ks (2022–2026), one primary filing per company. HTML cleaned (inline-XBRL/hidden/exhibit boilerplate stripped, sliced to the Item narrative), sentence-split with NLTK Punkt, junk/heading/fragment chunks removed.

  • Prototype scale — 38 queries; the query set skews toward charges (workforce answers more often repeat the company name and are filtered out to preserve the coreference axis).
  • Templated queries — 2 regex-generated templates (workforce, charges); phrasing overlaps the gold, so the difficulty is the coreference/near-duplicate disambiguation, not the wording. A natural/LLM-generated query pass is future work.
  • Evidence coverage — 28/38 queries have a supporting-evidence fragment; the rest are answer-only.

Source: public SEC EDGAR filings (U.S. government works / public domain).

Downloads last month
11

Collection including bowang0911/EDGAR8KContextChunkRetrieval